This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs crispr gene-editing gene-therapy genomics medical pharmaceuticals
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
by Zacks Equity Research
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
SNYPositive Net Change AGENNegative Net Change AMRNPositive Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
GSKPositive Net Change GILDPositive Net Change EXELPositive Net Change MIRMPositive Net Change
biotechs
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
by Zacks Equity Research
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
NVOPositive Net Change BAYRYPositive Net Change AGENNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
by Zacks Equity Research
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
by Zacks Equity Research
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
AZNPositive Net Change AGENNegative Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2
by Nalak Das
Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.
TRIPositive Net Change EXELPositive Net Change WWDPositive Net Change RGLDPositive Net Change SFMPositive Net Change
aerospace biotechs business-services gold retail
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
by Zacks Equity Research
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
RHHBYNegative Net Change NVOPositive Net Change BAYRYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends INCY's Application for Opzelura Label Expansion
by Zacks Equity Research
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
GSKPositive Net Change BAYRYPositive Net Change INCYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
JNJPositive Net Change ABBVPositive Net Change AGENNegative Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
by Zacks Equity Research
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
BMYPositive Net Change BNTXNegative Net Change CVACPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
by Zacks Equity Research
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
GSKPositive Net Change NVSPositive Net Change GILDPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
by Zacks Equity Research
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
INCYPositive Net Change EXELPositive Net Change AMRNPositive Net Change PBYINegative Net Change
biotechs
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
by Ahan Chakraborty
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical oncology-screening pharmaceuticals
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
by Sundeep Ganoria
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
NVSPositive Net Change BMYPositive Net Change VRTXPositive Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechs crispr gene-editing gene-therapy genomics medical pharmaceuticals
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
GSKPositive Net Change NVOPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs pharmaceuticals
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
LLYPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing medical pharmaceuticals
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
by Zacks Equity Research
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
BIIBPositive Net Change SUPNPositive Net Change
biotechs
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
by Zacks Equity Research
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
SNYPositive Net Change BMYPositive Net Change LLYPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals